Clinical cure and safe drug withdrawal in chronic hepatitis B
10.3760/cma.j.cn501113-20250106-00008
- VernacularTitle:慢性乙型肝炎临床治愈与安全停药
- Author:
Jieli HU
1
;
Yewei JI
1
;
Pai PENG
1
;
Hui FAN
1
;
Liuyang ZHAO
1
;
Haijun DENG
1
;
Ni TANG
1
;
Ailong HUANG
1
Author Information
1. 重庆医科大学感染性疾病分子生物学教育部重点实验室，重庆 400016
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Therapeutic;
Functional cure;
Discontinuation of nucleos-(t)ide analogues;
HBsAg;
Immune reconstitution
- From:
Chinese Journal of Hepatology
2025;33(6):526-533
- CountryChina
- Language:Chinese
-
Abstract:
With the widespread implementation of immunoprophylaxis strategies, the primary challenge in HBV infection prevention and control in China has shifted to reducing the burden of existing infections. A crucial approach to decreasing the burden of existing infections is to develop the effective treatment methods to achieve clinical or functional cures within a limited treatment duration for infected patients. The existing infections can be divided into two parts: those that are easy to cure and those that are difficult to treat. Patients who meet the current drug withdrawal criteria and at the same time have HBsAg<100 IU/mL following treatment with nucelos(t)ide analogue therapy are the easier one to treat, accounting for about 12% of the total infections, and the remaining 88% are difficult to cure. A necessary step toward clinical cure is pushing the HBsAg levels of patients to <100 IU/mL, but this driving effect must stem from effective immune reconstitution against HBV. Recent prevention and control, certain characteristics and implementation of clinical cure, and the safe drug withdrawal are discussed here to offer new perspectives on issues related to hepatitis B.
